{"id":10650,"date":"2009-05-22T00:00:00","date_gmt":"2009-05-22T00:00:00","guid":{"rendered":""},"modified":"-0001-11-30T00:00:00","modified_gmt":"-0001-11-30T04:00:00","slug":"hedge-fund-mgr-schoenfeld-backs-icahn-eastbourne-amylin-slate","status":"publish","type":"post","link":"https:\/\/hedgeco.net\/news\/05\/2009\/hedge-fund-mgr-schoenfeld-backs-icahn-eastbourne-amylin-slate.html","title":{"rendered":"Hedge Fund Mgr Schoenfeld Backs Icahn\/Eastbourne Amylin Slate"},"content":{"rendered":"<p>CNNMoney.com &#8211; A major shareholder of Amylin Pharmaceuticals Inc. ( AMLN) is backing a slate of dissident directors nominated by Carl Icahn and another hedge-fund manager, Eastbourne Capital Management.<\/p>\n<p>  P. Schoenfeld and Associates, which owned 2.1 million Amylin shares as of the end of the first quarter, told Dow Jones Newswires Thursday it supports all five of Icahn&#8217;s and Eastbourne&#8217;s nominees because it sees that as the only opportunity for the company to make significant strides.<\/p>\n<p>  &quot;We would like to see the largest minority possible elected to the Amylin board,&quot; said P. Schoenfeld founder Peter Schoenfeld.<\/p>\n<p><strong><a target=\"_blank\" href=\"http:\/\/www.hedgeco.net\/news\/news_land.php?i=http:\/\/money.cnn.com\/news\/newsfeeds\/articles\/djf500\/200905211447DOWJONESDJONLINE000782_FORTUNE5.htm\">Read Complete Article<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CNNMoney.com &#8211; A major shareholder of Amylin Pharmaceuticals Inc. ( AMLN) is backing a slate of dissident directors nominated by Carl Icahn and another hedge-fund manager, Eastbourne Capital Management. P. Schoenfeld and Associates, which owned 2.1 million Amylin shares as [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1024,12095,6838,1913,3813,10952,420,4589,37,12096,1099,510,3056],"class_list":["post-10650","post","type-post","status-publish","format-standard","hentry","category-syndicated","tag-1-million","tag-amln","tag-amylin-pharmaceuticals-inc","tag-capital-management","tag-carl-icahn","tag-dow-jones-newswires","tag-dow-jones","tag-first-quarter","tag-hedge-fund-manager","tag-schoenfeld","tag-shareholder","tag-slate","tag-strides"],"_links":{"self":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/10650","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=10650"}],"version-history":[{"count":0,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/10650\/revisions"}],"wp:attachment":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=10650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=10650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=10650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}